Most people who start a GLP-1 do not finish the first year on it. That is not a Denver problem, and it is not a willpower problem. It is a well-documented pattern, and the reasons behind it are specific enough that you can plan around them.
Here is what the research actually shows, and what it means if you are over 55 and trying to decide whether to start, continue or stop.
Half of Patients Stop Within a Year
A Danish population study of 77,310 adults taking semaglutide for weight loss found that 52% had discontinued within one year. The dropout was steady rather than sudden: about 18% by three months, 31% by six months, and 42% by nine months.
A separate US analysis of 125,474 adults found that within twelve months, 46.5% of patients with type 2 diabetes and 64.8% of patients without diabetes had stopped.
Those are large numbers from large datasets, and they line up. Roughly half of people stop within a year.
The Four Reasons People Actually Quit
1. Side effects they were not prepared for
Adverse reactions are the single most common documented reason, cited in about 27% of discontinuations in one real-world analysis. Nausea, reflux, constipation, and fatigue are the usual culprits, and they cluster around dose increases.
Most of these are manageable. Slower titration, timing meals differently, adjusting fiber and fluid, and pausing a dose escalation instead of pushing through all help. The people who quit are frequently the people who were escalated too fast and told to tough it out. If you want the practical version, we wrote up side effects and how to manage them.
At 5,280 feet, one detail matters more than it does at sea level. GI side effects cost you fluid, and Colorado’s dry air is already working against you. Dehydration makes nausea and fatigue worse, which makes quitting look more reasonable than it is. Hydration and electrolytes are worth taking seriously here.
2. Cost, and what happens at 65
Cost concerns drove about 14% of documented discontinuations. For older adults specifically, cost is the sharpest edge. Analyses using age 65 as a proxy for Medicare eligibility found that crossing that line was associated with a higher likelihood of stopping, which points squarely at coverage changes rather than at any clinical reason.
If you are approaching 65, this is a conversation to have before your coverage changes, not after. Options include compounded versus brand-name products, different agents such as tirzepatide, and dose strategies. What you should not do is buy from an unregulated online source, and we explained why in buying GLP-1s online.
3. Worry about muscle
This is the reason we hear most often from active Colorado patients in their sixties, and it deserves a straight answer.
Weight loss from GLP-1 medication is not all fat. Published estimates put lean body mass at roughly 15% to 40% of total weight lost. In younger adults, that is generally offset by the metabolic benefits. In older adults, it interacts with sarcopenia, the age-related loss of muscle mass and strength that is already underway.
The evidence is genuinely mixed and we will not pretend otherwise. Short and medium-term trials in adults with obesity have reported grip strength holding steady even as lean tissue declined. Longer retrospective work in older adults with type 2 diabetes has reported reduced grip strength and accelerated sarcopenia with prolonged use, particularly at higher doses and in people who already had low muscle mass.
What follows from that is not “avoid the medication.” It is “do not lose weight carelessly after 55.” Protein intake, resistance training two or three times a week, and measuring lean mass rather than just watching the scale are the difference between losing fat and losing your ability to hike Bear Creek. We covered the mechanics in what you may be losing along with the weight.
4. They hit their number and assumed they were done
This one is the most costly, because it is the most preventable.
Follow-up from the STEP 1 trial extension reported that participants who stopped semaglutide regained about two-thirds of their prior weight loss within a year. Obesity behaves like a chronic condition, and the medication treats it while it is being taken.
Stopping is a legitimate choice. Stopping without a maintenance plan is how people end up heavier than when they started, and weight cycling tends to bring back fat while leaving muscle behind. That trade is worse in your sixties than it was in your forties.
What Changes When You Do This With Supervision
Nearly every quit reason above is a clinical problem with a clinical answer.
Our medically supervised semaglutide program is built around the failure points, not just the prescription:
- Slower titration than the standard schedule when side effects appear, instead of pushing the dose and losing the patient.
- Lab work and monitoring, including frequent check-ins early when side effects are most likely.
- Body composition, not just body weight, so muscle loss is visible before it becomes a problem.
- Protein and strength guidance built into the plan. See the eating plan that supports the medication.
- A maintenance conversation before you need one, so the end of the medication is a plan rather than an event.
- Adjuncts where they fit, including the peptides that support growth hormone some patients ask about for muscle preservation.
For adults in this age range, hormone health is often part of the same picture. Low testosterone, thyroid changes, and menopause all affect body composition and energy, and they are worth evaluating alongside weight. That is what our hormone health program is for.
When Quitting Is the Right Call
We are not going to tell you that everyone should stay on. Stopping can be the right decision when:
- Side effects remain intolerable after a genuine attempt at slower titration and symptom management.
- You have developed a complication that warrants stopping.
- Muscle and functional measures are declining despite protein and resistance training.
- The cost is displacing something more important to your health.
- You have reached a stable weight and have a maintenance plan you and your clinician both believe in.
The bad version of quitting is the silent one. Stopping without telling anyone, with no plan, is what turns a year of progress into a year of regain.
If You Are Thinking About Stopping
Talk it through before you stop. Bring your labs, your current dose, what specifically is bothering you, and what you want your body to be able to do next summer.
Schedule your free consultation today.
This article provides general health information and is not medical advice. GLP-1 medications require a prescription and individualized medical supervision. Do not start, change, or stop a prescription medication based on a web page. Discuss any changes with your prescribing clinician.
Frequently Asked Questions
How many people stop taking GLP-1 medication in the first year?
About half. A Danish population study of 77,310 adults taking semaglutide for weight loss found 52% discontinued within one year, with roughly 18% stopping by three months and 42% by nine months. A US analysis of 125,474 adults found 46.5% of patients with type 2 diabetes and 64.8% of patients without diabetes had stopped within twelve months.
Why do older adults stop GLP-1 medication more often?
The documented drivers are side effects, cost and coverage. Adverse reactions accounted for about 27% of discontinuations in one real-world analysis and cost concerns about 14%. For older adults, analyses using age 65 as a proxy for Medicare eligibility found that reaching that age was associated with a higher likelihood of stopping, which points to coverage changes rather than a clinical reason.
Do GLP-1 medications cause muscle loss in older adults?
Some of the weight lost is lean tissue. Published estimates put lean body mass at roughly 15% to 40% of total weight lost. Evidence on function is mixed: some short- and medium-term trials found grip strength preserved despite lean tissue reduction, while longer retrospective studies in older adults with type 2 diabetes reported reduced grip strength and accelerated sarcopenia with prolonged use. Adequate protein, resistance training, and body composition monitoring are the standard responses.
Will I regain the weight if I stop semaglutide?
Regain is common. Follow-up from the STEP 1 trial extension reported that participants regained about two-thirds of their prior weight loss within a year of stopping. Obesity behaves like a chronic condition, so stopping without a maintenance plan usually leads to regain.
Can side effects be managed instead of quitting?
Frequently, yes. Nausea, constipation, and fatigue cluster around dose increases and often improve with slower titration, dose holds, hydration, electrolytes, and dietary adjustments. At Colorado’s altitude, fluid loss from GI side effects deserves particular attention. Talk to your prescriber before stopping.
Is it ever the right decision to stop a GLP-1?
Yes. Stopping can be appropriate when side effects remain intolerable after a real attempt at management, when a complication warrants it, when muscle and functional measures decline despite protein and training, when cost displaces higher-priority care, or when you have reached a stable weight and have a maintenance plan. The version to avoid is stopping without telling your clinician and without a plan.
Will Insurance Pay for Stem Cell Therapy in Denver?